These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 35553247

  • 1. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.
    Tartarone A, Lerose R, Tartarone M.
    Med Oncol; 2022 May 13; 39(7):107. PubMed ID: 35553247
    [Abstract] [Full Text] [Related]

  • 2. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J, Wu Y, Han R, Xu X, Waldeck R, Hu S.
    Adv Ther; 2023 Mar 13; 40(3):1087-1103. PubMed ID: 36630046
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Zhang X, Zhang G, Wang J, Bi J.
    Front Endocrinol (Lausanne); 2023 Mar 13; 14():1131033. PubMed ID: 36843606
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR.
    Adv Ther; 2022 Nov 13; 39(11):5025-5042. PubMed ID: 36028656
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2022 Jan 13; 39(1):518-531. PubMed ID: 34797506
    [Abstract] [Full Text] [Related]

  • 12. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U.
    Expert Opin Pharmacother; 2020 Dec 13; 21(17):2091-2099. PubMed ID: 32783772
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 13; 37(1):501-511. PubMed ID: 31813086
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective.
    Ingrosso G, Bottero M, Becherini C, Caini S, Alì E, Lancia A, Ost P, Sanguineti G, Siva S, Zilli T, Francolini G, Bellavita R, Aristei C, Livi L, Detti B.
    Semin Oncol; 2022 Oct 13; 49(5):409-418. PubMed ID: 36192243
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 13; 37(1):512-526. PubMed ID: 31813087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.